share_log

HC Wainwright & Co. Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

HC Wainwright & Co. Upgrades Oncternal Therapeutics to Buy, Announces $2 Price Target

HC Wainwright & Co.将 Oncternal Therapeutics 升级为收购,宣布目标价为 2 美元
Benzinga ·  2023/09/18 06:31

HC Wainwright & Co. analyst Raghuram Selvaraju upgrades Oncternal Therapeutics (NASDAQ:ONCT) from Neutral to Buy and announces $2 price target.

HC Wainwright&Co.分析师Raghuram Selvaraju将Oncent Treateutics(纳斯达克:ONCT)从中性上调至买入,并宣布目标价2美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发